HAL Lower Limb is a hybrid, bioelectric-controlled exoskeleton for clinical gait training. We break down its specs, deployment limits and who should avoid it.
ExoSelect researchContinue reading
Editorial QA
Checked for sourced parameters, internal links and prohibited claims.
If you are evaluating the HAL Lower Limb for a clinic, the first decision is not technical—it is commercial. Cyberdyne positions the system as a treatment or lease programme, not a box you buy and install. That single fact reshapes procurement: you are buying access to a care model, not a device.
Cyberdyne’s HAL Lower Limb is a cybernetic assistive limb that detects bioelectric signals from the user’s muscles to support hip and knee movement. It is not a passive frame; it is a hybrid system that blends signal-driven control with an autonomous gait mode. The database lists 2 degrees of freedom, 40 Nm assist torque, and a top speed of 1.5 km/h. The device weighs 17 kg and fits users from 145 to 190 cm and up to 100 kg.
For neurorehabilitation, the relevant control modes are bioelectric signal control and autonomous gait mode. The system includes bioelectric signal sensors, joint angle sensors and force sensors. Treatment data logging is supported, but connectivity is limited to that logging—there is no mention of a clinical software platform or session export comparable to what some competitors offer.
Three numbers drive daily scheduling. First, 3 hours of battery life means a typical therapy block may need a battery swap or a mid-day charge; the 2-hour charge time and swappable battery mitigate this, but you need a charging protocol. Second, the 1.5 km/h top speed is modest—fine for in-clinic gait training, but it limits overground distance work. Third, the 17 kg weight is lighter than the EksoNR (23.6 kg) but heavier than the Indego (12.3 kg); this affects therapist handling during donning and doffing.
The height range (145–190 cm) and user weight limit (100 kg) are standard for this class, but note that the Atalante X covers the same height range with a 100 kg limit, while the Indego extends to 113 kg. If your patient population includes heavier individuals, the HAL Lower Limb may exclude them.
| Spec | HAL Lower Limb | EksoNR | Indego | Atalante X |
|---|---|---|---|---|
| Maker | Cyberdyne | Ekso Bionics | Parker Hannifin | Wandercraft |
| Drive | Hybrid | Active | Active | Active |
| Weight | 17 kg | 23.6 kg | 12.3 kg | 65 kg |
| Assist torque | 40 Nm | 40 Nm | Unknown | Unknown |
| Speed | 1.5 km/h | 1.1 km/h | 2 km/h | 2.5 km/h |
| Degrees of freedom | 2 | 4 | 4 | 12 |
| Battery life | 3 h | 4 h | 4 h | 4 h |
| User weight limit | 100 kg | 100 kg | 113 kg | 100 kg |
| Certifications | CE medical, ISO 13485 | FDA, CE | FDA, CE | CE medical |
| Availability | Lease/treatment programme | Available on inquiry | Available on inquiry | Available on inquiry |
Only the HAL Lower Limb and EksoNR disclose assist torque (40 Nm). The Indego and Atalante X do not. If torque is a selection criterion, the field narrows quickly.
Three parameters are missing or unverified in the database, and each has procurement consequences.
Also missing: lead time is “programme-dependent” and warranty is 12 months—standard, but confirm what the lease covers. Clinical evidence is described as “clinical studies in stroke, SCI and neuromuscular conditions” without citations; request the specific papers and their outcome measures.
The HAL Lower Limb is available in Japan, Europe and Asia-Pacific. North American buyers are not listed as a region, which means US procurement would require a different regulatory and distribution path—if available at all. The certifications are CE medical and ISO 13485, with IEC 60601-1 compliance. There is no FDA clearance listed, unlike the EksoNR and Indego. For a US clinic, that is a material gap.
The lease or treatment programme model also changes the cost structure. Instead of a capital purchase with depreciation, you may face per-treatment or subscription fees. That can be attractive for pilot programmes but complicates multi-year budgeting and reimbursement mapping.
Do not choose the HAL Lower Limb if you need FDA clearance for US deployment, if you require documented peak assist force for patient-specific tuning, or if your patient mix includes individuals above 100 kg. Also avoid it if your procurement process demands a fixed capital price and a defined lead time—the programme model and “programme-dependent” lead time will not fit a standard equipment tender.
Conversely, the HAL Lower Limb is a reasonable candidate if you are in Japan, Europe or Asia-Pacific, you value bioelectric signal control as a differentiator, and you are prepared to engage in a treatment programme rather than a device purchase. The 40 Nm torque and 2 degrees of freedom are modest compared to the 4-DOF EksoNR, so if multi-joint complexity is a clinical priority, look elsewhere.
Cyberdyne typically offers it as a treatment or lease programme rather than a capital purchase. The database lists availability as “Lease or treatment programme” and price as undisclosed.
CE medical and ISO 13485, with compliance to IEC 60601-1. No FDA clearance is listed in the database.
The database states “Level walking; clinical assessment required” for climbing. Stair training is not listed as supported, unlike some competitors that explicitly exclude stairs.
Before you shortlist the HAL Lower Limb, request the programme terms and the specific clinical evidence from Cyberdyne. Then compare it side-by-side with the EksoNR and the Indego using our comparison tool. If you need help interpreting the gaps, contact the ExoSelect selection desk.
For official specifications, see Cyberdyne’s HAL Lower Limb medical page.
Editorial note
This analysis is based on published specifications and named sources. No first-party physical evaluation was performed.
Reviewed by the ExoSelect editorial desk
